▎WuXiEdited by Kant Content Team

Gilead Sciences and Xilio Therapeutics announced today an exclusive licensing agreement that could exceed $600 million in total value. The two companies will jointly develop and commercialize Xilio's tumor-activated therapies.Interleukin-12 (IL-12) ProteinXTX301, the drug currently under research is inClinical1Phase。

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of tumor-activated immuno-oncology therapies.The company is leveraging its proprietary tumor-activation platform to build a series of novel tumor-activating molecules,Including antibodies, cytokines, bispecific drugs, and cell engagers,Aimed at optimizing the therapeutic index and restricting the drug's antitumor activity to the tumor microenvironment.XTX301 is currently being evaluated in a Phase 1 dose-escalation trial for the treatment of patients with advanced solid tumors.

According to the terms of the agreement,Xilio Grants Gilead Global Exclusive License for Development and Commercialization of XTX301. Xilio will receive a $43.5 million upfront payment and is eligible for up to an additional $604 million in potential development, regulatory, and sales milestone payments.Xilio will be responsible for the development of the ongoing Phase 1 clinical trial of XTX301. After Xilio delivers the specified clinical data for XTX301, Gilead has the option to obtain the development and commercialization rights for XTX301 by paying a fee of $75 million. Prior to this, Xilio is eligible to receive additional investments and development milestone payments totaling up to $29 million.

▲XTX301 Protein (Image Source: Xilio Therapeutics, Inc. Official Website)

IL-12 is a pro-inflammatory cytokine designed to effectively stimulate anti-tumor immunity and reprogram the tumor microenvironment (TME) of poorly immunogenic "cold" tumors into an inflamed or "hot" state, offering potential for cancer immunotherapy.XTX301 is a half-life extended, shielded, tumor-activated IL-12 protein. XTX301 is designed to be pharmacologically inactive when circulating in non-tumor tissues and can be activated by matrix metalloproteinases (MMP) present in the tumor microenvironment.

Everyone is watching

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program. Retrieved March 28, 2024 from https://ir.xiliotx.com/news-releases/news-release-details/gilead-and-xilio-announce-exclusive-license-agreement-tumor

[2] John George Knecht et al., A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.. JCO 41, TPS2672-TPS2672(2023). DOI:10.1200/JCO.2023.41.16_suppl.TPS2672

Disclaimer:WuXi AppTec Content Team Focuses on Introducing Global Biomedical and Health Research Progress.This article is for informational exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned in the article.This article is not a recommendation for treatment options.For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.